Made by Delta Pharma Limited, Upacit XR Tablet is a er tablet whose active ingredient is Upadacitinib. Upadacitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
There are 2 brands of Upadacitinib listed in Bangladesh. By unit price, Upacit XR Tablet is among the cheapest of them.
What is Upacit XR Tablet 15 mg?
Upacit XR Tablet is a er tablet from Delta Pharma Limited, with the generic name Upadacitinib. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. The doctor decides the dose and course.
Uses of Upacit XR Tablet
Upadacitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. Ask your doctor whether it is right for your condition.
How to use Upacit XR Tablet
Upacit XR Tablet is taken by mouth. Swallow the er tablet with water. Complete the course exactly as prescribed. If you miss a dose, ask your doctor or pharmacist what to do.
Side effects of Upacit XR Tablet
Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.
Safety and precautions
Gastrointestinal Perforations : Use with caution in patients who may be at increased risk. The limited human data on use of Upadacitinib in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or miscarriage. Thrombosis : Consider the risks and benefits prior to treating patients who may be at increased risk of thrombosis. Keep out of reach of children.
Frequently asked questions
What does Upacit XR Tablet treat?
Upadacitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. Ask your doctor whether it is right for your condition.
How should I take Upacit XR Tablet?
Upacit XR Tablet is taken by mouth. Swallow the er tablet with water.
Can Upacit XR Tablet cause side effects?
Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.
Can I use Upacit XR Tablet in pregnancy or while breastfeeding?
Gastrointestinal Perforations : Use with caution in patients who may be at increased risk. The limited human data on use of Upadacitinib in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or miscarriage.
Upadacitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Pharmacology
Upadacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.
Dosage & Administration
The recommended dose of Upadacitinib is 15 mg once daily. Upadacitinib may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. Avoid initiation or interrupt Upadacitinib if absolute lymphocyte count is less than 500 cells/mm3, absolute neutrophil count is less than 1000 cells/mm3 or hemoglobin level is less than 8 g/dL.
Pediatric Use: The safety and efficacy of Upadacitinib in children and adolescents aged 0 to 18 years have not yet been established. No data are available.
Interaction
Strong CYP3A4 Inhibitors: Upadacitinib exposure is increased when co-administered with strong CYP3A4 inhibitors (such as ketoconazole). Upadacitinib should be used with caution in patients receiving chronic treatment with strong CYP3A4 inhibitors.
Strong CYP3A4 Inducers: Upadacitinib exposure is decreased when co-administered with strong CYP3A4 inducers (such as rifampin), which may lead to reduced therapeutic effect of Upadacitinib. Coadministration of Upadacitinib with strong CYP3A4 inducers is not recommended.
Side Effects
Adverse reactions (greater than or equal to 1%) are: upper respiratory tract infections, nausea, cough, and pyrexia.
Pregnancy & Lactation
The limited human data on use of Upadacitinib in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or miscarriage. Based on animal studies, upadacitinib has the potential to adversely affect a developing fetus. Advise not to breastfeed.
Precautions & Warnings
Serious Infections: Avoid use of Upadacitinib in patients with active, serious infection, including localized infections.
Malignancy: Consider the risks and benefits of Upadacitinib treatment prior to initiating therapy in patients with a known malignancy.
Thrombosis: Consider the risks and benefits prior to treating patients who may be at increased risk of thrombosis. Promptly evaluate patients with symptoms of thrombosis and treat appropriately.
Gastrointestinal Perforations: Use with caution in patients who may be at increased risk.
Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
Embryo-Fetal Toxicity: Upadacitinib may cause fetal harm based on animal studies. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.
Vaccinations: Avoid use of Upadacitinib with live vaccines.
Overdose Effects
Upadacitinib was administered in clinical trials up to doses equivalent in daily AUC to 60 mg extended-release once daily. Adverse events were comparable to those seen at lower doses and no specific toxicities were identified. Approximately 90% of upadacitinib in the systemic circulation is eliminated within 24 hours of dosing (within the range of doses evaluated in clinical studies). In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.
Storage Conditions
Do not store above 25°C. Protect from light. Keep out of reach of children.
Alternative brands of Upadacitinib
Other brands with the same generic name, cheapest first.